TCGA study of liver cancer reveals potential targets for therapy Only two drugs are FDA-approved for liver cancer. This study of hepatocellular carcinoma found genetic alterations in tumorsa��including mutations in tumor-suppressing genes and high expression of immune checkpoint genesa��that could be targets for drugs that already exist.

broker option navigator …read more Source:: Cancer